Get the Stockscreener App
28.32
2.42%
0.67
After Hours:
28.42
0.10
+0.35%
Avalyn Pharma Inc stock is traded at $28.32, with a volume of 375.38K.
It is up +2.42% in the last 24 hours and up +4.66% over the past month.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
See More
Previous Close:
$27.65
Open:
$28.27
24h Volume:
375.38K
Relative Volume:
1.36
Market Cap:
$1.26B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-13.97%
1M Performance:
+4.66%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$27.33
$29.19
1-Week Range:
$27.33
$32.92
52-Week Range:
$24.15
$33.32
Avalyn Pharma Inc Stock (AVLN) Company Profile
Name
Avalyn Pharma Inc
Sector
Industry
Phone
(206) 707-0340
Address
105 W FIRST ST., BOSTON
Compare AVLN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
28.32 | 1.23B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalyn Pharma Inc Stock (AVLN) Latest News
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Index - marketscreener.com
Avalyn Pharma Inc Actuals & Estimates (NASDAQ:AVLN) - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Value Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Growth Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 3000E Growth Benchmark - marketscreener.com
AVLN Forecast — Price Target — Prediction for 2027 - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell Small Cap Completeness Index - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2500 Value Benchmark - marketscreener.com
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Pharma (AVLN) Stock Chart and Price History 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs - BioPharma Dive
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Avalyn Pharma (AVLN) Earnings Date and Reports 2026 - MarketBeat
Avalyn Pharma (AVLN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Why is Avalyn Pharma stock surging today? By Investing.com - Investing.com UK
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone By Investing.com - Investing.com Canada
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial By Investing.com - Investing.com Australia
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis - The Manila Times
Avalyn Pharma Ord Shs (Proposed) (AVLN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead - inkl
Morgan Stanley Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Avalyn Pharma Inc. 2026 Q1 Financial Report and Material Risks Overview - Minichart
Avalyn Pharma 1Q Loss $26.9M >AVLN - Moomoo
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Inc. 1Q 2026: Net income $(26.9M), EPS $(21.83) — 10-Q Summary - TradingView
Avalyn: Q1 Earnings Snapshot - marketscreener.com
AVLN: Q1 2026 net loss widened to $26.9M; IPO proceeds extend cash runway into 2029, but more funding needed - TradingView
Avalyn Pharma (Nasdaq: AVLN) widens Q1 loss but extends cash runway into 2029 - Stock Titan
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves - Yahoo Finance
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
Avalyn Pharma Inc.: Target Price Consensus and Analysts Recommendations | AVLN | US05348Y1055 - marketscreener.com
Avalyn to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Avalyn, inhaled-therapy company for rare respiratory diseases, at Jefferies - Stock Titan
AVLN Initiated Coverage by Morgan Stanley -- Price Target Set at $53 - GuruFocus
AVLN Initiates Coverage by Guggenheim -- Price Target Announced at $80 - GuruFocus
Avalyn Pharma Inc Stock (AVLN) Financials Data
There is no financial data for Avalyn Pharma Inc (AVLN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Avalyn Pharma Inc Stock (AVLN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carroll Jill | Director |
May 01 '26 |
Buy |
18.00 |
277,778 |
5,000,004 |
2,186,562 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 01 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
2,186,562 |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):